PL2265279T3 - Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych - Google Patents

Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych

Info

Publication number
PL2265279T3
PL2265279T3 PL09761861T PL09761861T PL2265279T3 PL 2265279 T3 PL2265279 T3 PL 2265279T3 PL 09761861 T PL09761861 T PL 09761861T PL 09761861 T PL09761861 T PL 09761861T PL 2265279 T3 PL2265279 T3 PL 2265279T3
Authority
PL
Poland
Prior art keywords
nonapeptide
pat
treatment
autoimmune diseases
autoimmune
Prior art date
Application number
PL09761861T
Other languages
English (en)
Inventor
Jamal Temsamani
Claude Laruelle
Original Assignee
Cll Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cll Pharma filed Critical Cll Pharma
Publication of PL2265279T3 publication Critical patent/PL2265279T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL09761861T 2008-04-21 2009-04-15 Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych PL2265279T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0802220A FR2930156B1 (fr) 2008-04-21 2008-04-21 Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.
PCT/FR2009/000439 WO2009150310A1 (fr) 2008-04-21 2009-04-15 Utilisation du nonapeptide pat dans le traitement de maladies autoimmunes
EP09761861.5A EP2265279B1 (fr) 2008-04-21 2009-04-15 Utilisation du nonapeptide pat dans le traitement de maladies autoimmunes

Publications (1)

Publication Number Publication Date
PL2265279T3 true PL2265279T3 (pl) 2015-05-29

Family

ID=40024222

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09761861T PL2265279T3 (pl) 2008-04-21 2009-04-15 Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych

Country Status (6)

Country Link
US (1) US9427455B2 (pl)
EP (1) EP2265279B1 (pl)
JP (1) JP5536037B2 (pl)
FR (1) FR2930156B1 (pl)
PL (1) PL2265279T3 (pl)
WO (1) WO2009150310A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2962335B1 (fr) * 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7502830A (nl) * 1974-03-25 1975-09-29 Jean Francois Bach En Dr Jean Werkwijze voor het isoleren van een polypeptide hormoon.
US4098777A (en) * 1977-03-14 1978-07-04 Merck & Co., Inc. Process for the preparation of pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn
CH637111A5 (fr) * 1977-05-25 1983-07-15 Anvar Composes polypeptidiques a activite thymique ou antagoniste et leurs procedes de synthese.
DK221681A (da) * 1980-05-22 1981-11-23 Inst Nat Sante Fremgangsmaade til fremstilling af biologisk virksomme og radioimmunologisk anvendelige produkter ud fra serum-thymusfaktoren
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5808009A (en) * 1996-09-23 1998-09-15 North Dakota State University Research Foundation Method of affinity purifying antibodies
FR2830451B1 (fr) * 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur

Also Published As

Publication number Publication date
FR2930156B1 (fr) 2011-10-28
EP2265279B1 (fr) 2014-10-22
JP5536037B2 (ja) 2014-07-02
WO2009150310A1 (fr) 2009-12-17
EP2265279A1 (fr) 2010-12-29
US9427455B2 (en) 2016-08-30
JP2011518212A (ja) 2011-06-23
FR2930156A1 (fr) 2009-10-23
US20110098223A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
IL243538B (en) Artificial triterpenoids and methods for use in the treatment of disease
IL247183A0 (en) Secretory-apoptosis factors for the treatment of cancer and immune and autoimmune diseases
IL208845A (en) Progesterone antagonists such as 4124 CDB in the treatment of breast cancer
IL218851A0 (en) Use of dimiracetam in the treatment of chronic pain
PL2320900T3 (pl) Opioidy do zastosowania w leczeniu opornych pacjentów onkologicznych
GB2460181B (en) Depsipeptides and their therapeutic use
GB2460178B (en) Depsipeptides and their therapeutic use
SI2491005T1 (sl) Uporaba 4-(etil(dimetil)amonio)butanoata pri zdravljenju bolezni srca in oĺ˝ilja
GB0905970D0 (en) Depsipeptides and their therapeutic use
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
GB2460180B (en) Depsipeptides and their therapeutic use
FR2930156B1 (fr) Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.
GB0821594D0 (en) Improvements in or relating to the treatment of tissue damage
PL2593129T3 (pl) Nonapeptyd pat do stosowania w leczeniu choroby alzheimera
GB0809326D0 (en) Depsipeptides and their therapeutic use
GB0809324D0 (en) Depsipeptides and their therapeutic use
GB0809328D0 (en) Depsipeptides and their therapeutic use
GB0809330D0 (en) Depsipeptides and their therapeutic use
GB201015789D0 (en) Peptides and their use in the treatment
GB0904043D0 (en) The treatment of raynaud's phenomenon
GB0820562D0 (en) Novel use and treatment
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB0814920D0 (en) Peptides and their use in treatment